GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Infections, Intestinal Clinical Trial

Official title: A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infection in Adults

Status Terminated

Clinical Trial Summary

This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Infections, Intestinal
• Intraabdominal Infections

• NCT number: NCT01381562
• Study type: Interventional
• Source: GlaxoSmithKline
• Status: Terminated
• Phase: Phase 2
• Start date: October 3, 2011
• Completion date: March 5, 2012